Fabry disease (FD) is a multisystemic disorder caused by pathogenic variants in the α-galactosidase (GLA) gene. There is ongoing debate on the disease-causing properties of the GLA variant NM_000169.3: c.937G > T, p.Asp313Tyr (D313Y). Like many others, we recently reclassified this variant from “variant of uncertain significance” to “benign.” By leveraging Centogene's Biodatabank, we reassessed our classification and analyzed all samples (n = 38,242) molecularly tested for FD from Germany between 2015 and 2020 for GLA genotypes, clinical presentations, and biochemical phenotypes. The allele frequency of GLA variant p.Asp313Tyr in our cohort was increased compared with gnomAD v4.1.0 data for European (non-Finnish) population resulting in an odds ratio of 2.13 (95% CI 1.94–2.33; p < 0.0001). Compared with individuals without any GLA variant, there was no specific clinical nor biochemical phenotype in this group, supporting a diagnosis of FD. GLA variant p.Asp313Tyr is to be classified as a benign variant and does not cause FD. Because an enrichment of patients with this variant in specific high-risk populations has been seen in this cohort and by other groups, properly designed case-control studies are needed to clarify a potential role of p.Asp313Tyr as risk factor or modifier of a FD-independent dysfunction.